Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P4HA3 siRNA
- Development stage
- Preclinical
- Lead developer
- UT Health San Antonio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
P4HA3 siRNA is a small interfering RNA designed to silence the expression of the prolyl-4-hydroxylase α subunit 3 (P4HA3) gene. P4HA3 is a key enzyme involved in collagen synthesis, specifically catalyzing the conversion of proline residues to 4-hydroxyproline, which is essential for the stability of mature collagen. In the context of oncology, particularly renal cell carcinoma (RCC) and gastric cancer, P4HA3 acts as a tumor promoter by facilitating extracellular matrix remodeling that supports tumor progression and metastasis. By knocking down P4HA3, this siRNA inhibits cancer cell proliferation, migration, and invasion. Research has demonstrated its potential in preclinical models of RCC, where it significantly reduced tumor growth in mouse xenografts.
- Other names
- P4HA3 small interfering RNAP-4HA3 small interfering RNAP 4HA3 small interfering RNA
02
Targets
P4H (Prolyl 4-hydroxylase subunit alpha-3)Innate immune RNA pattern-recognition receptors
Beyond the preview
Go deeper on P4HA3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P4HA3 siRNA.